Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
Boehringer Ingelheim has filed for a label expansion of Hernexeos (zongertinib) in Japan, seeking approval for use as a first-line treatment in patients with HER2 (ERBB2)-mutated unresectable, advanced or recurrent non-small cell lung cancer (NSCLC). Hernexeos hit the Japanese market…
To read the full story
Related Article
- Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
November 20, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
BUSINESS
- Santen Eyes Pterygium Drug as Key Pipeline Asset, 4 Million Potential Patients in Japan
March 23, 2026
- Chugai Files Device Component of Ranibizumab Eye Implant in Japan
March 23, 2026
- Shionogi’s Zurzuvae, Kissei’s Yselty Now Available in Japan
March 23, 2026
- Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
March 23, 2026
- Novo Japan Logs 5.4% Growth in 2025, Sees Wegovy Powering Push for Double-Digit Goal
March 23, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…